Table 8.

Cardiotoxicity of anticancer drugs apart from chemotherapy agents [18]

Sl. No.	Anticancer drug	Cardiotoxicity profile
1	HER2is: 1.Monoclonal antibodies: trastuzumab and pertuzumab 2.Tyrosine kinase inhibitor: lapatinib	LVSD and HF
2	VEGFi	Hypertension, myocardial ischemia, LVSD, QTc prolongation, arterial thromboembolic events
3	mTORi	Hypertension, myocardial ischemia, LVSD, QTc prolongation, arterial thromboembolic events, hypercholesterolemia, hypertriglyceridemia, hyperglycemia
4	Bcr-Abl kinasei (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib)	Accelerated atherosclerosis, peripheral artery disease, acute coronary syndrome, stroke, hypertension, hyperglycemia, hypercholesterolemia, pericardial effusion, pulmonary arterial hypertension, QTc prolongation, and occasional LVSD
5	Proteasome inhibitors (carfilzomib, bortezomib, ixazomib)	LVSD, HF, arterial hypertension, myocardial ischemia
6	Ibrutinib	Atrial fibrillation, hypertension, HF, ventricular arrhythmias, conduction disorders
7	Immune checkpoint inhibitors	Immune-related myocarditis, pericarditis, supraventricular arrhythmias, acute coronary syndrome, and Takotsubo syndrome